Table 2 Characteristics of the patients with U. urealyticum, U. parvum, and M. hominis positivity
|  | Ureaplasma urealyticum (n = 17) | Ureaplasma parvum (n = 19) | Mycoplasma hominis (n = 13) |  ≥ two pathogens (n = 6) |
|---|---|---|---|---|
Clinical symptoms, n (%) | ||||
 Drowsiness | 2 (11.8) | 2 (10.5) | 1 (7.7) | 2 (33.3) |
 Coma | 5 (29.4) | 10 (52.6) | 4 (30.8) | 2 (33.3) |
 Epilepsy | 0 (0) | 2 (10.5) | 0 (0) | 0 (0) |
History of transplantation, n (%) | ||||
 Kidney | 4 (23.5) | 0(0) | 0(0) | 1 (16.7) |
 Lung | 0 (0) | 3 (15.8) | 1 (7.7) | 0 (0) |
Antimicrobial treatment before clinical metagenomics testing, n (%) | ||||
 Macrolides | 1 (5.9) | 0 (0) | 0 (0) | 0 (0) |
 Quinolones | 2 (11.8) | 4 (21.1) | 1 (7.7) | 1 (16.7) |
 Blood ammonia test, n (%) | 4 (23.5) | 4 (21.1) | 4 (30.8) | 1 (16.7) |
 Blood ammonia, median (IQR) | 69.5 (38.2, 132.2) | 22.5 (10.2, 34.2) | 36.8 (30.9, 39.0) | 432.0 |
 Head CT scan, n (%) | 11 (64.7) | 14 (73.7) | 9 (69.2) | 5 (83.3) |
 Cerebral edema | 2 (18.2) | 9 (64.3) | 3 (33.3) | 1 (20.0) |
 Lumbar puncture, n (%) | 1 (5.9) | 3 (15.8) | 2 (15.4) | 3 (50.0) |
 Intracranial pressure, cm H2O, median (IQR) | 270.0 | 170.0 (127.5,310.0) | 250.0 (250.0,250.0) | 200.0 (150.0,240.0) |
Therapeutic drug, n (%) | ||||
 Macrolides | 1 (5.9) | 0(0) | 0(0) | 2 (33.3) |
 Quinolones | 2 (11.8) | 4 (21.1) | 3 (23.1) | 3 (50.0) |
 Tetracyclines | 2 (11.8) | 1 (5.3) | 1 (7.7) | 0(0) |
 Improvement in patients with treatment, n (%) | 2 (40.0) | 3 (60.0) | 2 (50.0) | 4 (80.0) |